Premium
Time‐dependent clearance of mycophenolic acid in renal transplant recipients
Author(s) -
Van Hest Reinier M.,
Van Gelder Teun,
Bouw René,
Goggin Timothy,
Gordon Robert,
Mamelok Richard D.,
Mathot Ron A.
Publication year - 2007
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.2006.02841.x
Subject(s) - mycophenolic acid , pharmacokinetics , transplantation , renal function , urology , creatinine , population , medicine , renal transplant , kidney transplantation , population pharmacokinetics , nonmem , therapeutic drug monitoring , chemistry , pharmacology , environmental health
Aims Pharmacokinetic studies of the immunosuppressive compound mycophenolic acid (MPA) have shown a structural decrease in clearance (CL) over time after renal transplantation. The aim of this study was to characterize the time‐dependent CL of MPA by means of a population pharmacokinetic meta‐analysis, and to test whether it can be described by covariate effects. Methods One thousand eight hundred and ninety‐four MPA concentration‐time profiles from 468 renal transplant patients (range 1–9 profiles per patient) were analyzed retrospectively by nonlinear mixed effect modelling. Sampling occasions ranged from day 1–10 years after transplantation. Results The pharmacokinetics of MPA were described by a two‐compartment model with time‐lagged first order absorption, and a first‐order term for time‐dependent CL. The model predicted the mean CL to decrease from 35 l h −1 (CV = 44%) in the first week after transplantation to 17 l h −1 (CV = 38%) after 6 months. In a covariate model without a term for time‐dependent CL, changes during the first 6 months after transplantation in creatinine clearance from 19 to 71 ml min −1 , in albumin concentration from 35 to 40 g l −1 , in haemoglobin from 9.7 to 12 g dl −1 and in cyclosporin predose concentration from 225 to 100 ng ml −1 corresponded with a decrease of CL from 32 to 19 l h −1 . Creatinine clearance, albumin concentration, haemoglobin and cyclosporin predose concentration explained, respectively, 19%, 12%, 4% and 3% of the within‐patient variability in MPA CL. Conclusions By monitoring creatinine clearance, albumin concentration, haemoglobin and cyclosporin predose concentration, changes in MPA exposure over time can be predicted. Such information can be used to optimize therapy with mycophenolate mofetil.